Device Trial Radar · NCT07802119
Transjugular Approach for Implantation of Active Fixation Leadless Pacemakers
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Oct 10, 2026
Primary completion
Sep 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Min ShenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 3, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, single-arm, single-center feasibility study evaluating the safety and feasibility of transjugular (internal jugular vein) implantation of the Aveir VR leadless ventricular pacemaker in patients requiring ventricular pacing. A total of 15 patients will be enrolled at Xijing Hospital. The primary objective is to assess procedural feasibility and acute safety (from intraoperative to 48 hours post-procedure). Secondary objectives include short-term (1 to 3 months) pacing parameter stability (threshold, R-wave amplitude, impedance), technical success rate, procedure-related metrics, and adverse event rates.
Conditions
- Bradycardia
- Heart Block
- Sick Sinus Syndrome
- Atrioventricular Block
Interventions
Aveir VR Leadless PacemakerDevice
The Aveir VR leadless pacemaker is implanted via a transjugular (jugular vein) approach. This active-fixation device is placed in the right ventricle for ventricular pacing indications.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Participants with Sustained Successful Aveir VR Lead Implantation (evaluated by fluoroscopy and clinical-electrophysiological follow-up)Time frame: Through 3 months post-procedure
- Acute adverse event rateTime frame: Periprocedural and up to 48 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xijing Hospital, The First Affiliated Hospital of Air Force Medical University
Xi'an, Shaanxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.